Yesterday, Simulations Plus announced it has accepted an invitation and signed a formal agreement to take part in the European Union Oral Bioavailability Tools (OrBiTo) project. Simulations Plus, a leader in providing simulation and modeling software for pharmaceutical discovery and development, has the honor of being the only non-European company that was invited to participate.
The OrBiTo project was created as part of the Innovative Medicines Initiative Joint Undertaking (IMI-JU). This new collaboration is intended to advance various tools - including computer software - that are used for predicting oral absorption of drugs. This will be accomplished by sharing data and technologies across the OrBiTo member companies.
A multiyear collaboration, the OrBiTo project will involve a total of 27 companies - from the largest pharmaceutical companies in the world to small companies, including some software companies. Simulations Plus will be the only company to participate that does not have an operational office in a European country. This distinction is a tribute to the company's reputation for superior science and software on a global scale. Simulations Plus intends to leverage this invitation in its own marketing efforts, as well as with other OrBiTo member organizations. As a non-European member, Simulations Plus will receive funding for its efforts and also be granted access to important data to be shared equally among members. The company will thereby be in a better position to serve its European customers.
Simulations Plus is a leading developer of pioneering drug discovery and development simulation and modeling software - licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies throughout the world. Simulations Plus also provides a productivity tool called Abbreviate! for PCs. The company is headquartered in Southern California.
For more information, visit www.simulations-plus.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html